- Home
- DNLI vs GOF Comparison
DNLI vs GOF Comparison
Compare DNLI & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNLI | GOF |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | DNLI | GOF |
|---|---|---|
| Price | $18.66 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $31.58 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 789.2K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3,973.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.57 | $10.96 |
| 52 Week High | $24.35 | $16.76 |
Technical Indicators
Market Signals| Indicator | DNLI | GOF |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.43 |
| Support Level | N/A | $12.68 |
| Resistance Level | N/A | $13.07 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 51.69 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.